Modified treatment for hemophagocytic lymphohistiocytosis
Part of Blood & lymphatic clinical trials.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 70 years old and have been diagnosed with HLH (hemophagocytic lymphohistiocytosis), a rare condition where the immune system overreacts and damages organs.
- Your liver and kidney function must be within acceptable levels (for example, bilirubin no more than 10 times the normal upper limit, creatinine no more than 1.5 times normal, and fibrinogen corrected to at least 0.6 g/L).
- You must not have active hepatitis B, hepatitis C, or HIV. If you test positive for hepatitis B or C, your viral levels must be low and controlled.
- If you are a woman who can become pregnant, you must not be pregnant and must use effective contraception during the study and for at least 6 months after. Men must use contraception during the study and for 3 months after.
- You must not have severe heart problems, including heart failure or a history of high-dose anthracycline chemotherapy that affected your heart.
- You must not have severe uncontrolled infections or active major bleeding (like in the gut, lungs, or brain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This Phase 2 study tests ruxolitinib as a first treatment for primary HLH, a rare, sometimes life-threatening immune overreaction. It may help calm the immune system and improve symptoms by blocking key immune signals.
Hear when a new Hemophagocytic Lymphohistiocytoses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.